Nektar Therapeutics Cash Flow Statement
NASDAQ: NKTRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
41.17+0.37 (+0.91%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nektar Therapeutics free cash flow
In fiscal 2025, Nektar Therapeutics generated -$208.5 million of operating cash flow and spent $171,000 on capital expenditures. That left free cash flow of -$208.7 million, a free-cash-flow margin of -377.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Nektar Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -164.08M | -118.96M | -276.06M | -368.20M | -523.84M | -444.44M | -440.67M | 681.31M | -96.69M | -153.52M |
| Net Income growth (YoY) | — | — | — | — | — | — | -164.68% | — | — | — |
| Depreciation & Amortization | 1.03M | 4.10M | 7.00M | 12.20M | 13.00M | 12.50M | 11.00M | 8.80M | 12.60M | 13.20M |
| Stock-Based Compensation | 12.65M | 21.61M | 33.39M | 57.32M | 94.67M | 94.26M | 99.80M | 88.10M | 36.62M | 25.85M |
| Change in Working Capital | -16.07M | -4.07M | -10.95M | 2.11M | -25.92M | 664.00K | 3.25M | -68.63M | -34.88M | -4.28M |
| Operating Cash Flow | -208.51M | -175.71M | -192.61M | -304.01M | -412.66M | -313.29M | -328.68M | 718.21M | -80.41M | -117.02M |
| Capital Expenditures | -171.00K | -1.47M | -865.00K | -5.68M | -14.99M | -7.26M | -26.29M | -14.24M | -9.68M | -6.39M |
| Investing Cash Flow | -1.20M | 142.57M | 139.56M | 365.83M | 202.78M | 496.21M | 206.89M | -1.38B | -28.81M | -82.40M |
| Share Repurchases | 0 | -3.00M | 0 | — | — | — | — | — | — | — |
| Debt Repaid | — | — | — | 0 | 0 | -250.00M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 180.57M | 42.12M | 30.00K | 1.51M | 36.24M | -80.35M | 23.36M | 851.97M | 54.39M | 203.62M |
| Net Change in Cash | -29.14M | 8.97M | -52.95M | 63.01M | -173.74M | 102.59M | -98.54M | 190.14M | -54.88M | 4.07M |
| Free Cash Flow | -208.68M | -177.18M | -193.47M | -309.68M | -427.65M | -320.55M | -354.97M | 703.98M | -90.09M | -123.42M |
This table shows 10 annual periods of Nektar Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NKTR's reporting calendar. What is a cash flow statement?